Aurisco Pharmaceutical Co Ltd
SSE:605116
Income Statement
Earnings Waterfall
Aurisco Pharmaceutical Co Ltd
Revenue
|
1.2B
CNY
|
Cost of Revenue
|
-519.3m
CNY
|
Gross Profit
|
642.3m
CNY
|
Operating Expenses
|
-383.7m
CNY
|
Operating Income
|
258.6m
CNY
|
Other Expenses
|
-1.6m
CNY
|
Net Income
|
257m
CNY
|
Income Statement
Aurisco Pharmaceutical Co Ltd
Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||
Revenue |
677
N/A
|
688
+2%
|
721
+5%
|
727
+1%
|
741
+2%
|
767
+4%
|
803
+5%
|
836
+4%
|
911
+9%
|
983
+8%
|
1 008
+3%
|
1 091
+8%
|
1 052
-4%
|
1 162
+10%
|
|
Gross Profit | |||||||||||||||
Cost of Revenue |
(331)
|
(336)
|
(381)
|
(403)
|
(412)
|
(419)
|
(409)
|
(406)
|
(446)
|
(502)
|
(496)
|
(564)
|
(527)
|
(519)
|
|
Gross Profit |
346
N/A
|
352
+2%
|
340
-3%
|
324
-5%
|
329
+2%
|
348
+6%
|
395
+13%
|
430
+9%
|
465
+8%
|
481
+4%
|
513
+7%
|
528
+3%
|
525
-1%
|
642
+22%
|
|
Operating Income | |||||||||||||||
Operating Expenses |
(143)
|
(149)
|
(143)
|
(138)
|
(150)
|
(163)
|
(202)
|
(224)
|
(238)
|
(260)
|
(297)
|
(302)
|
(329)
|
(384)
|
|
Selling, General & Administrative |
(107)
|
(106)
|
(97)
|
(97)
|
(102)
|
(110)
|
(130)
|
(141)
|
(152)
|
(161)
|
(172)
|
(191)
|
(209)
|
(251)
|
|
Research & Development |
(44)
|
(49)
|
(39)
|
(49)
|
(54)
|
(57)
|
(60)
|
(90)
|
(97)
|
(110)
|
(107)
|
(111)
|
(118)
|
(132)
|
|
Depreciation & Amortization |
0
|
0
|
(12)
|
0
|
0
|
0
|
(21)
|
0
|
0
|
0
|
(25)
|
0
|
0
|
0
|
|
Other Operating Expenses |
9
|
6
|
5
|
8
|
6
|
5
|
9
|
7
|
11
|
11
|
7
|
(0)
|
(2)
|
(1)
|
|
Operating Income |
203
N/A
|
204
+0%
|
197
-3%
|
185
-6%
|
178
-4%
|
186
+4%
|
193
+4%
|
205
+7%
|
226
+10%
|
221
-2%
|
216
-2%
|
225
+5%
|
196
-13%
|
259
+32%
|
|
Pre-Tax Income | |||||||||||||||
Interest Income Expense |
7
|
(7)
|
(9)
|
(17)
|
(15)
|
(7)
|
2
|
1
|
16
|
33
|
27
|
23
|
18
|
32
|
|
Non-Reccuring Items |
(1)
|
(1)
|
(2)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(0)
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
34
|
36
|
0
|
(1)
|
(0)
|
(1)
|
(2)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
|
Pre-Tax Income |
244
N/A
|
232
-5%
|
186
-20%
|
167
-10%
|
163
-3%
|
178
+9%
|
192
+8%
|
205
+7%
|
241
+17%
|
253
+5%
|
241
-5%
|
246
+2%
|
211
-14%
|
290
+37%
|
|
Net Income | |||||||||||||||
Tax Provision |
(27)
|
(25)
|
(29)
|
(27)
|
(25)
|
(27)
|
(24)
|
(29)
|
(39)
|
(33)
|
(33)
|
(33)
|
(23)
|
(35)
|
|
Income from Continuing Operations |
217
|
207
|
157
|
140
|
137
|
150
|
168
|
176
|
201
|
221
|
208
|
213
|
189
|
255
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
3
|
1
|
2
|
|
Net Income (Common) |
217
N/A
|
207
-5%
|
157
-24%
|
140
-11%
|
137
-2%
|
151
+10%
|
169
+12%
|
177
+5%
|
202
+14%
|
222
+9%
|
211
-5%
|
216
+2%
|
190
-12%
|
257
+35%
|
|
EPS (Diluted) |
0.68
N/A
|
0.55
-19%
|
0.42
-24%
|
0.34
-19%
|
0.35
+3%
|
0.37
+6%
|
0.42
+14%
|
0.44
+5%
|
0.5
+14%
|
0.55
+10%
|
0.53
-4%
|
0.54
+2%
|
0.47
-13%
|
0.64
+36%
|